{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:06:20Z","timestamp":1779314780685,"version":"3.51.4"},"reference-count":20,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jval.2025.11.011","type":"journal-article","created":{"date-parts":[[2025,12,6]],"date-time":"2025-12-06T07:50:41Z","timestamp":1765007441000},"page":"731-738","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Influence of Initial Imaging Modality on Peri-Diagnostic Outcomes Among Pancreatic, Liver, Ovarian, and Bladder Cancers Without Routine Screening Programs: A Surveillance, Epidemiology, and End Results-Medicare Study"],"prefix":"10.1016","volume":"29","author":[{"given":"Xiting","family":"Cao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Brouwer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yilin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dave","family":"Veenstra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Tyson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seema","family":"Rego","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omair","family":"Choudhry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jon","family":"Ebbert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jval.2025.11.011_bib2","first-page":"183","article-title":"Recent progress in the diagnosis and treatment of ovarian cancer","volume":"61","author":"Jelovac","year":"2011","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jval.2025.11.011_bib3","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1002\/cncr.33211","article-title":"Patients with hepatocellular carcinoma from more rural and lower-income households have more advanced tumor stage at diagnosis and significantly higher mortality","volume":"127","author":"Wong","year":"2021","journal-title":"Cancer"},{"issue":"suppl 4","key":"10.1016\/j.jval.2025.11.011_bib4","doi-asserted-by":"crossref","first-page":"iv238","DOI":"10.1093\/annonc\/mdy308","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"29","author":"Vogel","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jval.2025.11.011_bib5","doi-asserted-by":"crossref","first-page":"S92","DOI":"10.1038\/bjc.2015.48","article-title":"Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic review","volume":"112","author":"Neal","year":"2015","journal-title":"Br J Cancer"},{"issue":"11S","key":"10.1016\/j.jval.2025.11.011_bib6","doi-asserted-by":"crossref","first-page":"S384","DOI":"10.1016\/j.jacr.2019.05.014","article-title":"ACR appropriateness Criteria\u00ae palpable abdominal mass-suspected neoplasm","volume":"16","author":"Fowler","year":"2019","journal-title":"J Am Coll Radiol"},{"issue":"1","key":"10.1016\/j.jval.2025.11.011_bib7","first-page":"42","article-title":"Diagnostic imaging: appropriate and safe use","volume":"103","author":"Ford","year":"2021","journal-title":"Am Fam Physician"},{"issue":"2","key":"10.1016\/j.jval.2025.11.011_bib8","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10147-025-02694-5","article-title":"Transforming cancer screening: the potential of multi-cancer early detection (MCED) technologies","volume":"30","author":"Imai","year":"2025","journal-title":"Int J Clin Oncol"},{"issue":"55","key":"10.1016\/j.jval.2025.11.011_bib9","first-page":"3","article-title":"Updated overview of the SEER-Medicare data: enhanced content and applications","volume":"2020","author":"Enewold","year":"2020","journal-title":"J Natl Cancer Inst Monogr"},{"issue":"12","key":"10.1016\/j.jval.2025.11.011_bib11","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1016\/j.jclinepi.2004.03.012","article-title":"New ICD-10 version of the Charlson comorbidity index predicted in-hospital mortality","volume":"57","author":"Sundararajan","year":"2004","journal-title":"J Clin Epidemiol"},{"issue":"3","key":"10.1016\/j.jval.2025.11.011_bib12","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1136\/bmjqs-2024-017506","article-title":"Experiences with diagnostic delay among underserved racial and ethnic patients: a systematic review of the qualitative literature","volume":"34","author":"Faugno","year":"2025","journal-title":"BMJ Qual Saf"},{"issue":"2","key":"10.1016\/j.jval.2025.11.011_bib14","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1002\/cncr.30316","article-title":"Relation of comorbidities and patient navigation with the time to diagnostic resolution after abnormal cancer screening","volume":"123","author":"Whitley","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.jval.2025.11.011_bib15","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h176","article-title":"Managing patients with multimorbidity in primary care","volume":"350","author":"Wallace","year":"2015","journal-title":"BMJ"},{"issue":"638","key":"10.1016\/j.jval.2025.11.011_bib17","doi-asserted-by":"crossref","first-page":"446","DOI":"10.3399\/bjgp15X686401","article-title":"New NICE guidance on diagnosing cancer in general practice","volume":"65","author":"Emery","year":"2015","journal-title":"Br J Gen Pract"},{"issue":"12","key":"10.1016\/j.jval.2025.11.011_bib18","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/j.healthpol.2016.09.008","article-title":"The 2015 National Cancer Program in Sweden: introducing standardized care pathways in a decentralized system","volume":"120","author":"Wilkens","year":"2016","journal-title":"Health Policy"},{"issue":"6","key":"10.1016\/j.jval.2025.11.011_bib20","doi-asserted-by":"crossref","first-page":"e643","DOI":"10.1200\/JOP.2015.009605","article-title":"Typical time to treatment of patients with lung cancer in a multisite, US-based study","volume":"12","author":"Vidaver","year":"2016","journal-title":"J Oncol Pract"},{"key":"10.1016\/j.jval.2025.11.011_bib21","doi-asserted-by":"crossref","DOI":"10.1155\/2015\/285096","article-title":"Missed opportunities for the diagnosis of colorectal cancer","volume":"2015","author":"Siminoff","year":"2015","journal-title":"Biomed Res Int"},{"issue":"12","key":"10.1016\/j.jval.2025.11.011_bib22","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.6004\/jnccn.2018.7067","article-title":"Delays in diagnosis and treatment of breast cancer: a safety-net population profile","volume":"16","author":"Jaiswal","year":"2018","journal-title":"J Natl Compr Canc Netw"},{"issue":"5","key":"10.1016\/j.jval.2025.11.011_bib23","first-page":"370","article-title":"Variability in resource use: diagnosing colorectal cancer","volume":"19","author":"Srygley","year":"2013","journal-title":"Am J Manag Care"},{"issue":"6","key":"10.1016\/j.jval.2025.11.011_bib24","first-page":"659","article-title":"Time duration and health care resource use during cancer diagnoses in the United States: a large claims database analysis","volume":"29","author":"Gitlin","year":"2023","journal-title":"J Manag Care Spec Pharm"},{"issue":"16","key":"10.1016\/j.jval.2025.11.011_bib25","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1200\/JCO.2024.42.16_suppl.1622","article-title":"Diagnostic test use and time to cancer diagnosis in Medicare recipients","volume":"42","author":"Chung","year":"2024","journal-title":"J Clin Oncol"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525061492?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301525061492?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T21:15:49Z","timestamp":1779311749000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301525061492"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":20,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S1098301525061492"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2025.11.011","relation":{},"ISSN":["1098-3015"],"issn-type":[{"value":"1098-3015","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Influence of Initial Imaging Modality on Peri-Diagnostic Outcomes Among Pancreatic, Liver, Ovarian, and Bladder Cancers Without Routine Screening Programs: A Surveillance, Epidemiology, and End Results-Medicare Study","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2025.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}